Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.37 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.32 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.31 |
| ▸ | PDE4A | P27815 | 1/20 | 0.31 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.31 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.31 |
| ▸ | PDE8B | O95263 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25340772 | 0.76 | KMT2A (0.43) | HRH4PDE4DKDM4EALDH1A1GAA | |
| SCHEMBL25342386 | 0.71 | MAPT (0.38) | HRH4PDE10AKDM4EALDH1A1MAPT | |
| SCHEMBL1282292 | 0.71 | NUDT1 (0.40) | PDE10AKDM4EALDH1A1GAAMAPT | |
| SCHEMBL1681670 | 0.70 | CKS1B (0.42) | PDE10AKDM4EALDH1A1GAAMAPT | |
| SCHEMBL5052617 | 0.69 | PDE10A (0.43) | PDE10AKDM4EALDH1A1GAAMAPT | |
| SCHEMBL24392421 | 0.69 | PDE10A (0.44) | HRH4PDE10APDE4D | |
| SCHEMBL24392424 | 0.67 | PDE10A (0.35) | HRH4PDE10APDE4DPDE4APDE4B | |
| SCHEMBL13317331 | 0.67 | GAA (0.32) | KDM4EALDH1A1GAAMAPTHPGD | |
| SCHEMBL20088499 | 0.67 | PDE10A (0.38) | HRH4PDE10APDE4DKDM4EPDE4A | |
| SCHEMBL20088505 | 0.67 | PDE4D (0.33) | HRH4PDE10APDE4DPDE4APDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025032214-A1 | INDAZOLE COMPOUNDS AND AZAINDAZOLE COMPOUNDS AS INHIBITORS OF RAF KINASES | PIERRE FABRE MEDICAMENT (FR) | 2025-02-13 | — | — | WO | disclosed |
| EP-4472968-A1 | INHIBITORS OF RAF KINASES | PIERRE FABRE MEDICAMENT (FR) | 2024-12-11 | — | — | EP | disclosed |
| CN-118974036-A | Inhibitors of RAF kinase | 皮埃尔法布雷医药公司 | 2024-11-15 | — | — | CN | disclosed |
| US-20240182467-A1 | INHIBITORS OF RAF KINASES | Pierre Fabre Médicament (FR) | 2024-06-06 | — | — | US | disclosed |
| US-11814384-B2 | Inhibtors of Raf kinases | KINNATE BIOPHARMA INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-20230303566-A1 | INHIBITORS OF RAF KINASES | Pierre Fabre Médicament (FR) | 2023-09-28 | — | — | US | disclosed |
| WO-2023150681-A1 | INHIBITORS OF RAF KINASES | KINNATE BIOPHARMA INC. (US) | 2023-08-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240182467-A1 | INHIBITORS OF RAF KINASES | BRAF, RAF1, ARAF | HRH4 3053/4885PDE10A 3310/4885PDE4D 3169/4885 |
| US-20230303566-A1 | INHIBITORS OF RAF KINASES | BRAF, RAF1, ARAF | HRH4 3053/4885PDE10A 3310/4885PDE4D 3169/4885 |
| US-11814384-B2 | Inhibtors of Raf kinases | RAF1, BRAF, ARAF | HRH4 4134/4885PDE10A 3476/4885PDE4D 2997/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.